Our study uncovered a novel molecular mechanism of lncRNA SNHG4 in driving prostate cancer progression and enzalutamide resistance, revealing the critical roles and therapeutic potential of RREB1, SNHG4 and let-7 miRNAs in anticancer therapy. Here, SNHG4 is linked to prostate cancer.